Nvidia Corp vs Smith & Nephew plc — how do they compare? Nvidia Corp trades at $219.36 (market cap $5.27T), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Nvidia Corp is far larger — about 420.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| NVDA | SNN | |
|---|---|---|
Market Cap | $5.27T | $12.54B |
Sector | Technology | Health |
52-Week High | $235.75 | $38.70 |
52-Week Low | $165.17 | $28.73 |
Enterprise Value | $5.20T | $15.57B |
Dividend Yield | 0.46% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $217.56, down 2.86% over the past 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97% and robust cash flow from operations of $64.09B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $325.86.
The outlook for NVDA is favorable, supported by accelerating AI chip demand and a dominant market position. Key opportunities include sustained revenue growth and expanding profitability, while risks involve heightened competition, potential peak AI spending, and market volatility. The stock's current valuation metrics, such as a P/E of 33.31, reflect high growth expectations that must be met to justify further upside.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →